Clinical Trials Arena on MSN12d
ImmunoGenesis doses first subject in Phase I/II trial of hypoxia reversal agent
ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...
Nature9y
Transient hypoxia reprograms differentiating adipocytes for enhanced insulin sensitivity and triglyceride accumulation
Preadipocytes were exposed to transient hypoxia (4 h day −1) in the course of differentiation. Insulin sensitivity and triglyceride (TG) accumulation was examined in the cells at the end of ...